1,882
Views
4
CrossRef citations to date
0
Altmetric
Epidemiology

Case-control study in ALS using the National ALS Registry: lead and agricultural chemicals are potential risk factors

, , , , , , , , , , , , & show all
Pages 190-202 | Received 13 Dec 2020, Accepted 24 May 2021, Published online: 17 Jun 2021

References

  • Writing G, Edaravone A. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16:505–12.
  • Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919–30.
  • Ajroud-Driss S, Siddique T. Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim Biophys Acta. 2015;1852:679–84.
  • van den Berg LH, Sorenson E, Gronseth G, Macklin EA, Andrews J, Baloh RH, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92:e1610–e23.
  • Al-Chalabi A, Hardiman O. The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013;9:617–28.
  • Riancho J, Bosque-Varela P, Perez-Pereda S, Povedano M, de Munain AL, Santurtun A. The increasing importance of environmental conditions in amyotrophic lateral sclerosis. Int J Biometeorol. 2018;62:1361–74.
  • Kamel F, Umbach DM, Munsat TL, Shefner JM, Hu H, Sandler DP. Lead exposure and amyotrophic lateral sclerosis. Epidemiology. 2002;13:311–9.
  • Kamel F, Umbach DM, Hu H, Munsat TL, Shefner JM, Taylor JA, et al. Lead exposure as a risk factor for amyotrophic lateral sclerosis. Neurodegener Dis. 2005;2:195–201.
  • Fang F, Peters TL, Beard JD, Umbach DM, Keller J, Mariosa D, et al. Blood lead, bone turnover, and survival in amyotrophic lateral sclerosis. Am J Epidemiol. 2017;186:1057–64.
  • Malek AM, Barchowsky A, Bowser R, Heiman-Patterson T, Lacomis D, Rana S, et al. Environmental and occupational risk factors for amyotrophic lateral sclerosis: a case-control study. Neurodegener Dis. 2014;14:31–8.
  • Filippini T, Tesauro M, Fiore M, Malagoli C, Consonni M, Violi F, et al. Environmental and occupational risk factors of amyotrophic lateral sclerosis: a population-based case-control study. Int J Environ Res Public Health. 2020;17:2882.
  • Meng E, Mao Y, Yao Q, Han X, Li X, Zhang K, et al. Population-based study of environmental/occupational lead exposure and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci. 2020;41:35–40.
  • Gunnarsson LG, Bodin L. Amyotrophic lateral sclerosis and occupational exposures: a systematic literature review and meta-analyses. Int J Environ Res Public Health. 2018;15:2371.
  • Riancho J, Sanchez de la Torre JR, Paz-Fajardo L, Limia C, Santurtun A, Cifra M, et al. The role of magnetic fields in neurodegenerative diseases. Int J Biometeorol. 2021;65:107–17.
  • Luna J, Leleu JP, Preux PM, Corcia P, Couratier P, Marin B, et al. Residential exposure to ultra high frequency electromagnetic fields emitted by Global System for Mobile (GSM) antennas and amyotrophic lateral sclerosis incidence: a geo-epidemiological population-based study. Environ Res. 2019;176:108525.
  • Vinceti M, Malagoli C, Fabbi S, Kheifets L, Violi F, Poli M, et al. Magnetic fields exposure from high-voltage power lines and risk of amyotrophic lateral sclerosis in two Italian populations. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:583–9.
  • Peters S, Visser AE, D’Ovidio F, Beghi E, Chio A, Logroscino G, et al. Associations of electric shock and extremely low-frequency magnetic field exposure with the risk of amyotrophic lateral sclerosis. Am J Epidemiol. 2019;188:796–805.
  • D’Amico E, Factor-Litvak P, Santella RM, Mitsumoto H. Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013;65:509–27.
  • Chetty CS, Vemuri MC, Campbell K, Suresh C. Lead-induced cell death of human neuroblastoma cells involves GSH deprivation. Cell Mol Biol Lett. 2005;10:413–23.
  • Qian Y, Zheng Y, Ramos KS, Tiffany-Castiglioni E. The involvement of copper transporter in lead-induced oxidative stress in astroglia. Neurochem Res. 2005;30:429–38.
  • Fowler BA, Whittaker MH, Lipsky M, Wang G, Chen XQ. Oxidative stress induced by lead, cadmium and arsenic mixtures: 30-day, 90-day, and 180-day drinking water studies in rats: an overview. Biometals. 2004;17:567–8.
  • Prasanthi RP, Devi CB, Basha DC, Reddy NS, Reddy GR. Calcium and zinc supplementation protects lead (Pb)-induced perturbations in antioxidant enzymes and lipid peroxidation in developing mouse brain. Int J Dev Neurosci. 2010;28:161–7.
  • Ahamed M, Siddiqui MK. Low level lead exposure and oxidative stress: current opinions. Clin Chim Acta. 2007;383:57–64.
  • Shadnia S, Azizi E, Hosseini R, Khoei S, Fouladdel S, Pajoumand A, et al. Evaluation of oxidative stress and genotoxicity in organophosphorus insecticide formulators. Hum Exp Toxicol. 2005;24:439–45.
  • Franco R, Sanchez-Olea R, Reyes-Reyes EM, Panayiotidis MI. Environmental toxicity, oxidative stress and apoptosis: menage a trois. Mutat Res. 2009;674:3–22.
  • Schmuck G, Rohrdanz E, Tran-Thi QH, Kahl R, Schluter G. Oxidative stress in rat cortical neurons and astrocytes induced by paraquat in vitro. Neurotox Res. 2002;4:1–13.
  • Muniz JF, McCauley L, Scherer J, Lasarev M, Koshy M, Kow YW, et al. Biomarkers of oxidative stress and DNA damage in agricultural workers: a pilot study. Toxicol Appl Pharmacol. 2008;227:97–107.
  • Mbah Ntepe LJ, Habib R, Judith LN, Raza S, Nepovimova E, Kuca K, et al. Oxidative stress and analysis of selected SNPs of ACHE (rs 2571598), BCHE (rs 3495), CAT (rs 7943316), SIRT1 (rs 10823108), GSTP1 (rs 1695), and Gene GSTM1, GSTT1 in chronic organophosphates exposed groups from Cameroon and Pakistan. Int J Mol Sci. 2020;21:6432.
  • Blasco H, Garcon G, Patin F, Veyrat-Durebex C, Boyer J, Devos D, et al. Panel of oxidative stress and inflammatory biomarkers in ALS: a pilot study. Can J Neurol Sci. 2017;44:90–5.
  • Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, et al. Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler. 2008;9:177–83.
  • Simpson EP, Yen AA, Appel SH. Oxidative stress: a common denominator in the pathogenesis of amyotrophic lateral sclerosis. Curr Opin Rheumatol. 2003;15:730–6.
  • Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study). Amyotroph Lateral Scler. 2006;7:241–5.
  • Eisen A, Kiernan M, Mitsumoto H, Swash M. Amyotrophic lateral sclerosis: a long preclinical period? J Neurol Neurosurg Psychiatry. 2014;85:1232–8.
  • Factor-Litvak P, Al-Chalabi A, Ascherio A, Bradley W, Chio A, Garruto R, et al. Current pathways for epidemiological research in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14: 33–43.
  • Mehta P, Antao V, Kaye W, Sanchez M, Williamson D, Bryan L, et al. Prevalence of amyotrophic lateral sclerosis – United States, 2010–2011. MMWR Suppl. 2014;63:1–14.
  • Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. Prevalence of amyotrophic lateral sclerosis – United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67:1285–9.
  • Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, et al. ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:192–203.
  • Rabkin JG, Goetz R, Factor-Litvak P, Hupf J, McElhiney M, Singleton J, et al. Depression and wish to die in a multicenter cohort of ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:265–73.
  • Rabkin J, Goetz R, Murphy JM, Factor-Litvak P, Mitsumoto H, Group ACS. Cognitive impairment, behavioral impairment, depression, and wish to die in an ALS cohort. Neurology. 2016;87:1320–8.
  • Nieves JW, Gennings C, Factor-Litvak P, Hupf J, Singleton J, Sharf V, et al. Association between dietary intake and function in amyotrophic lateral sclerosis. JAMA Neurol. 2016;73:1425–32.
  • Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, et al. Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort. Neurology. 2016;86:813–20.
  • Horton DK, Graham S, Punjani R, Wilt G, Kaye W, Maginnis K, et al. A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:126–33.
  • Nelson LM, Tanner CM, Van Den Eeden S, McGuire VM, editors. Neuroepidemiology. From principles to practice. New York, NY: Oxford University Press; 2004.
  • Wacholder S, Silverman DT, McLaughlin JK, Mandel JS. Selection of controls in case-control studies. II. Types of controls. Am J Epidemiol. 1992;135:1029–41.
  • Ann DH. The occupational environment: its evaluation, control, and management. Falls Church, VA: American Industrial Hygiene Association Press; 2014.
  • Louis ED, Jurewicz EC, Applegate L, Factor-Litvak P, Parides M, Andrews L, et al. Association between essential tremor and blood lead concentration. Environ Health Perspect. 2003;111:1707–11.
  • Bowman JD, Touchstone JA, Yost MG. A population-based job exposure matrix for power-frequency magnetic fields. J Occup Environ Hyg. 2007;4:715–28.
  • Pearce N. Analysis of matched case-control studies. BMJ. 2016;352:i969.
  • Weisskopf MG, Seals RM, Webster TF. Bias amplification in epidemiologic analysis of exposure to mixtures. Environ Health Perspect. 2018;126:047003.
  • Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. New York, NY: Oxford University Press; 1998:18–33.
  • Mitsumoto H, Garofalo DC, Santella RM, Sorenson EJ, Oskarsson B, Fernandes JAM, Jr, et al. Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:263–72.
  • Loikkanen J, Naarala J, Vahakangas KH, Savolainen KM. Glutamate increases toxicity of inorganic lead in GT1-7 neurons: partial protection induced by flunarizine. Arch Toxicol. 2003;77:663–71.
  • Kriscenski-Perry E, Durham HD, Sheu SS, Figlewicz DA. Synergistic effects of low level stressors in an oxidative damage model of spinal motor neuron degeneration. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:151–7.
  • Sahin E., Gümüşlü S. Alterations in brain antioxidant status, protein oxidation and lipid peroxidation in response to different stress models. Behav Brain Res. 2004;155:241–8.
  • Quandt SA, Jones BT, Talton JW, Whalley LE, Galvan L, Vallejos QM, et al. Heavy metals exposures among Mexican farmworkers in eastern North Carolina. Environ Res. 2010;110:83–8.
  • Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:9–18.
  • Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm. 2005;112:649–60.
  • Kaufmann P, Thompson JL, Levy G, Buchsbaum R, Shefner J, Krivickas LS, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:235–44.
  • Hupf JFL, Goetz R, et al. ARREST ALS: an extension of the ALS COSMOS study. Amyotroph Lateral Scler Frontotemporal Degener. 2018;176–7.
  • Beard JD, Steege AL, Ju J, Lu J, Luckhaupt SE, Schubauer-Berigan MK. Mortality from amyotrophic lateral sclerosis and Parkinson’s disease among different occupation groups – United States, 1985–2011. MMWR Morb Mortal Wkly Rep. 2017;66:718–22.